TrialAssure discounts pricing for academics: ‘It is crucial for universities to get it right’

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/noipornpan)
(Image: Getty/noipornpan)
The global software provider is discounting its reporting software for academics, as universities globally struggle with compliance and face increasing pressure to publish clinical trial results.

TrialAssure Academic Pricing (TAP) provides the company’s clinical trial registration and disclosure reporting application at a discounted price. The offering enables sponsors and academic researchers to manage the disclosure process, including registry assessments, validation and quality checks, review cycles, approvals, as well as comments from regulatory authorities.

“In an academic setting, it can be more difficult to obtain public-ready information from investigators and other contributors to the study. When a study completes, the primary focus is on analyzing results and getting published, with transparency obligations often taking a back seat,”​ Zach Weingarden, product solutions manager, TrialAssure, told us.

Between pharmaceutical companies and universities, Weingarden said the penalties are viewed differently.

He explained, “For pharma companies, there is the potential of fines of up to $10,000/day and the general poor stigma of being non-compliant or not transparent is bad for the company’s image. While that is also true for universities, the bigger issue is that most leading scientific journals require clinical trial disclosures be up-to-date or they will refuse to publish any of the results.”

Additionally, the National Institutes of Health (NIH) can withhold funding for other studies.

“These two areas are much more impactful for continued funding and research at the academic level, so it is crucial for universities to get it right,”​ added Weingarden.

Only 11% of universities post clinical trial results to the European Clinical Trial Register (EUCTR) within the required timeframe, according to a report published in The BMJ​.

Clamping down on compliance, the Chair of the Science and Technology Select Committee, Norman Lamb MP, recently wrote to more than forty UK universities​. The committee plans to question institutions later this year following a debrief with AllTrials, which will be monitoring compliance.

In the US, a study in BMC Medicine​ found that approximately 35% of universities have a policy addressing clinical trial results reporting and 74% do not have electronic transparency system to manage reporting.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars